- Home
- JKS vs ORKA Comparison
JKS vs ORKA Comparison
Compare JKS & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKS | ORKA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | JKS | ORKA |
|---|---|---|
| Price | $24.02 | $65.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $25.25 | ★ $70.00 |
| AVG Volume (30 Days) | 448.6K | ★ 1.0M |
| Earning Date | 03-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.55 | $8.36 |
| 52 Week High | $31.88 | $67.50 |
Technical Indicators
Market Signals| Indicator | JKS | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 75.29 |
| Support Level | $23.78 | $26.02 |
| Resistance Level | $26.17 | N/A |
| Average True Range (ATR) | 1.01 | 3.80 |
| MACD | -0.01 | 1.25 |
| Stochastic Oscillator | 41.69 | 90.38 |
Price Performance
Historical ComparisonAbout JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.